Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Cangrelor

An intravenous antiplatelet drug that blocks the P2Y12 receptor, approved in 2015 to prevent clot formation during coronary angioplasty. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It is an ATP analogue: it acts within about two minutes and, because it is broken down directly in the blood, platelet function returns to normal about an hour after the infusion ends.

CangrelorGo to the active ingredient →
CangrelorActive ingredientCangrelorCat. No. P-C020-001CAS 163706-06-7

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.